• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by InflaRx N.V.

    6/27/25 4:05:32 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IFRX alert in real time by email
    6-K 1 ef20051261_6k.htm 6-K
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 6-K

    Report of Foreign Private
    Issuer Pursuant to Rule
    13a-16 or 15d-16 under the
    Securities Exchange Act
    of 1934
    For the month of June 2025
    Commission File
    Number: 001-38283

    InflaRx N.V.

    Winzerlaer Str. 2
    07745 Jena,
    Germany
    (+49) 3641508180

    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒ Form 40-F  ☐



    OTHER INFORMATION
     
    Change in Certifying Accountant
     
    On June 26, 2025, InflaRx N.V. (the “Company”) executed an engagement letter with KPMG AG Wirtschaftsprüfungsgesellschaft (“KPMG”) to engage KPMG as its independent registered public accounting firm for the fiscal year ended December 31, 2025. In connection with this engagement, the Company ceased to engage EY GmbH & Co. KG Wirtschaftsprüfungsgesellschaft (“EY”) as its independent registered public accounting firm. EY had served as the Company’s independent registered public accounting firm since the fiscal year ended December 31, 2020. The change in independent registered public accounting firm follows the results of the Company’s Annual General Meeting of Shareholders held, in accordance with Dutch law, on April 24, 2025, where the Company’s shareholders voted to approve KPMG Accountants N.V. for the external audit of the Company’s statutory annual accounts for the fiscal year ended December 31, 2025. The Company’s decision to make the change in auditor was not due to any disagreement with EY. EY did not resign or decline to stand for re-election and EY’s reports on the Company’s financial statements as of and for the year ended December 31, 2024 and as of and for the year ended December 31, 2023 and on internal control over financial reporting as of December 31, 2024 and as of December 31, 2023 were not qualified and did not contain an adverse or disclaimer of opinion.
     
    The Company will provide the additional disclosures in accordance with Item 16F regarding the predecessor auditor in its Form 20-F for the fiscal year ending December 31, 2025.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    Date: June 27, 2025
     
     
    INFLARX N.V.
       
     
    By:
    /s/ Niels Riedemann
       
    Niels Riedemann
       
    Chief Executive Officer
     


    Get the next $IFRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IFRX

    DatePrice TargetRatingAnalyst
    5/29/2025$2.00Strong Buy → Outperform
    Raymond James
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/5/2023$8.00Neutral → Buy
    Guggenheim
    2/28/2022Buy → Neutral
    Guggenheim
    11/8/2021$14.00 → $15.00Strong Buy
    Raymond James
    10/28/2021$14.00Outperform → Strong Buy
    Raymond James
    8/6/2021$11.00 → $10.00Outperform
    Raymond James
    8/6/2021$2.80 → $2.50Underperform
    Credit Suisse
    More analyst ratings